Patents
Literature
5 results about "Aprotinin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The drug aprotinin (Trasylol, previously Bayer and now Nordic Group pharmaceuticals), is a small protein bovine pancreatic trypsin inhibitor (BPTI), or basic trypsin inhibitor of bovine pancreas, which is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes. Under the trade name Trasylol, aprotinin was used as a medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use was to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; this was confirmed by follow-up studies. Trasylol sales were suspended in May 2008, except for very restricted research use. In February 2012 the European Medicines Agency (EMA) scientific committee reverted its previous standpoint regarding aprotinin, and has recommended that the suspension be lifted. Nordic became distributor of aprotinin in 2012.
Aprotinin affinity chromatographic column as well as preparation method and application thereof
The invention provides a preparation method of an aprotinin affinity chromatographic column. Specifically, the aprotinin is used as a raw material and is coupled with CNBr activated agarose gel Focurose 4FF to prepare the aprotinin affinity chromatographic column. The coupling reaction in the preparation method is simple and easy to control, the reaction condition is mild, the operation is convenient, the repeatability is high, and industrial amplification is easy. The affinity column prepared by the invention can completely remove human urinary kallidinogenase in urokinase, and can be repeatedly used for multiple times.
Owner:JIANGSU AIDEA PHARMACEUTICAL CO LTD +1
Oral ulcer pasting film and preparation method thereof
ActiveCN121622623ADigestive systemMacromolecular non-active ingredientsPolyvinyl alcoholPhosphorylation
The invention discloses an oral ulcer pasting film and a preparation method thereof, and belongs to the field of medicine, the oral ulcer pasting film comprises a double-layer film layer and a carrier layer loading the film layer; the double-layer film layer comprises an outer film layer and an inner film layer which are tightly attached to each other; the outer film layer is attached to the carrier layer; the inner membrane layer is prepared from the following components in parts by weight: 20 to 25 parts of phosphorylated chitosan, 15 to 20 parts of polyvinyl alcohol, 10 to 12 parts of glutin and 3 to 5 parts of a TG enzyme-aprotinin compound; the outer film layer is prepared from the following components in parts by weight: 35 to 40 parts of temperature-sensitive salt shrinkage polymer, 20 to 25 parts of carboxylated protein and 8 to 10 parts of glyceryl monostearate; the carrier layer is prepared from the following components in parts by weight: 70 to 80 parts of hydrophilic fiber-gelatin modifier, 6 to 8 parts of saliva stimulating factor and 15 to 20 parts of glycerol. The film of the present invention can maintain good structural flatness.
Owner:ONE STATE HEALTHCARE TECH (YUNNAN) CO LTD
Preparation method of macromolecular d-dimer and application thereof
PendingCN122146830AImmunoglobulins against blood coagulation factorsBiological testingDimerAprotinin
The application discloses a preparation method and application of macromolecular D-dimer, and first finds that tannic acid or glutaraldehyde is used as a coagulation accelerator, and EDTA or aprotinin is used as a fibrinolysis terminator, so that the macromolecular D-dimer can be efficiently prepared in vitro; and a stable, repeatable and large-scale preparation process for the macromolecular D-dimer is first established. The application provides key raw materials and technical support for precise diagnosis and dynamic monitoring of thrombus, and has a wide application prospect.
Owner:NAT HEALTH COMMISSION INST OF SCI & TECH
Recombinant aprotinin, its gene and method of production
The present application relates to a kind of recombinant aprotinin and its coding gene and preparation method, the preparation method is in the N end of the sequence of bovine aprotinin sequence and adds a sequence consisting of 21 amino acids, the recombinant aprotinin sequence is composed of 79 amino acids, molecular weight 8.812kD, isoelectric point 9.42.And a kind of rapid purification method is established, and the molecular weight of about 8.8kD of recombinant aprotinin can be quickly separated and purified by two-step chromatography, the activity recovery rate of whole purification process is high, specific activity >4.0EPU / mg, about 400mg of recombinant aprotinin pure product can be obtained per liter of fermentation liquor.The whole purification step is simple, the loss of target protein is less, the potency of obtained product is high, and the yield per liter of fermentation liquor is high, suitable for large-scale production application.
Owner:HEFEI MEINUO BIOTECHNOLOGY CO LTD
An oral ulcer patch and a preparation method thereof
ActiveCN121622623BImprove barrier propertiesImprove the protective effectDigestive systemMacromolecular non-active ingredientsPolyvinyl alcoholPhosphorylation
The application discloses an oral ulcer film and a preparation method thereof, and belongs to the medical field. The oral ulcer film comprises a double-layer film layer and a carrier layer of a loaded film layer. The double-layer film layer comprises a tightly adhered outer film layer and an inner film layer. The outer film layer is adhered to the carrier layer. The inner film layer comprises the following components in weight fractions: 20-25 parts of phosphorylated chitosan, 15-20 parts of polyvinyl alcohol, 10-12 parts of gelatin protein and 3-5 parts of a TG enzyme-antipain complex. The outer film layer comprises the following components in weight fractions: 35-40 parts of a temperature-sensitive salt condensation polymer, 20-25 parts of a carboxylated protein and 8-10 parts of glycerol monostearate. The carrier layer comprises the following components in weight fractions: 70-80 parts of a hydrophilic fiber-gelatin modifier, 6-8 parts of a saliva stimulating factor and 15-20 parts of glycerol. The film can maintain good structural flatness.
Owner:ONE STATE HEALTHCARE TECH (YUNNAN) CO LTD